Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
UPJ INSIGHT Predictors of Financial Toxicity Among United States Prostate Cancer Survivors: A National Survey
By: Benjamin V. Stone, MD, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, Massachusetts General Hospital, Boston; Muhieddine Labban, MD, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; Dejan K. Filipas, MD, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; Edoardo Beatrici, MD, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; Nicola Frego, MD, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; Zhiyu (Jason) Qian, MD, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; Sandeep S. Voleti, MPH, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; Stuart R. Lipsitz, ScD, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; Adam S. Kibel, MD, Brigham and Women’s Hospital, Boston, Massachusetts; Quoc-Dien Trinh, MD, MBA, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; Alexander P. Cole, MD, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts | Posted on: 19 Sep 2023
Stone BV, Labban M, Filipas DK, et al. Predictors of financial toxicity among United States prostate cancer survivors: results from a national survey. Urol Pract. 2023;10(5):459-466.
Study Need and Importance
Cancer survivorship in the United States is associated with high rates of financial toxicity. Prostate cancer is the most common noncutaneous malignancy in American men, but the burden of financial toxicity in prostate cancer survivors has not been well characterized.
In this study we sought to assess the prevalence of subjective and objective measures of financial toxicity among prostate cancer survivors using the Medical Expenditure Panel Survey Cancer Self-administered Questionnaire. We also aimed to identify the predictors of financial toxicity in this cohort to identify those most at risk.
What We Found
Among 412 respondents with a history of prostate cancer, representative of 2,349,532 men after application of survey weights, there were high rates of both subjective and objective measures of financial toxicity (see Table). Of respondents, 13.5% reported catastrophic health care expenditures or out-of-pocket health care costs greater than 10% of annual income. On multivariable logistic regression analysis, significant predictors of catastrophic health care expenditures included private insurance (OR 4.62, 95% CI 1.29-16.49) and medical comorbidities (OR 1.38, 95% CI 1.05-1.82), while high income was protective (>400% vs <100% federal poverty level, OR 0.06, 95% CI 0.02-0.19). Each year of older age was associated with decreased odds of subjective worry about medical bills. Only 12% of men reported their doctor discussed the costs of care in detail.
Table. Measures of Financial Toxicity in the Study Cohort
No. | % | |
---|---|---|
Worry about paying medical bills | 400 | 15.9 |
Using food stamps | 405 | 3.5 |
Unable to cover medical bills | 400 | 6.6 |
Early retirement | 205 | 12.0 |
Borrow money or in debt | 398 | 2.5 |
Change in work due to cancer | 412 | 15.3 |
Delay or forgo cancer treatment due to cost | 72 | 6.8 |
Delay or forgo prescriptions due to cost | 72 | 14.3 |
Delay or forgo specialist visit due to cost | 72 | 13.7 |
Worry about income instability | 240 | 13.0 |
Cut spending on basic needs (eg, food and clothing) | 103 | 12.5 |
Catastrophic health expenditures | 412 | 13.5 |
Limitations
Limitations of this study include the use of survey data, which are subject to recall bias. Additionally, robust clinical data on treatment modality and disease severity are not available in the Medical Expenditure Panel Survey data set.
Interpretation for Patient Care
This study demonstrates the rates of subjective and objective measures of financial toxicity in a nationally representative prostate cancer population. These data may inform counseling to ensure patients are well informed about cost implications of prostate cancer and may guide interventions such as financial counseling for those most at risk, particularly young, privately insured men with low income.
advertisement
advertisement